Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine.

Antimicrobial agents and chemotherapy - 1 Apr 2004

Stone Chris, Ait-Khaled Mounir, Craig Charles, Griffin Philip, Tisdale Margaret

Abstract excerpt

Mutations selected or deselected during passage of human immunodeficiency virus strain HXB2 or resistant variants with tenofovir (TFV), abacavir (ABC), and lamivudine (3TC) differed depending on the drug combination and virus genotype. In the wild-type virus, TFV-ABC and TFV-3TC selected K65R (wi...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Dideoxynucleosides
Share to Drug Combinations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lamivudine

Share to Organophosphonates

Share to Organophosphorus Compounds

Share to Tenofovir

Source

Open in PubMed Open full text

Identifiers

PMID: 15047556
DOI: 10.1128/AAC.48.4.1413-1415.2004
PMCID: PMC375323

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-15047556-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine.PMID 15047556Read ↗

In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.Semantic proximity Read ↗

Selection of K65R mutation in HIV-2-infected patients receiving tenofovir-containing regimen.Semantic proximity Read ↗

Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors.Semantic proximity Read ↗

Comprehensive database of HIV mutations selected during antiretroviral in vitro passage experiments.Semantic proximity Read ↗

Evolution of tenofovir-resistant HIV-1 isolates exposed to tenofovir alafenamide dose escalation.Semantic proximity Read ↗

Selection of L74V mutation in reverse transcriptase of HIV-1 subtype D by a tenofovir DF-lamivudine based regimen.Semantic proximity Read ↗

Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021).Semantic proximity Read ↗

Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug.Semantic proximity Read ↗

Nucleoside and nucleotide analogs select in culture for different patterns of drug resistance in human immunodeficiency virus types 1 and 2.Semantic proximity Read ↗

Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.Semantic proximity Read ↗

Different Evolution of Genotypic Resistance Profiles to Emtricitabine Versus Lamivudine in Tenofovir-Containing RegimensSemantic proximity Read ↗

HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.